Modification of myocardial substrate utilisation: A new therapeutic paradigm in cardiovascular disease

Heart

Volumn 96, Issue 11, 2010, Pages 824-830

  Beadle, Roger M ^a   Frenneaux, Michael ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMINO ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOMOXIR; FATTY ACID; GLUCOSE; GLUCOSE INSULIN POTASSIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LACTIC ACID; OXYGEN; PERHEXILINE MALEATE; PROPRANOLOL; RANOLAZINE; TRIMETAZIDINE; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMPREHENSION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; ENERGY; ENERGY METABOLISM; ENERGY RESOURCE; FATTY ACID OXIDATION; GLUCOSE INTAKE; GLUCOSE OXIDATION; HEART; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HUMAN; HYPOGLYCEMIA; LIVER DISEASE; MODEL; NONHUMAN; OMNIVORE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; STABLE ANGINA PECTORIS;

ADENOSINE TRIPHOSPHATE; BLOOD GLUCOSE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; FATTY ACIDS; HUMANS; MITOCHONDRIA, HEART; MYOCARDIUM; OXIDATION-REDUCTION; OXYGEN CONSUMPTION;

EID: 77953717010     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.190256     Document Type: Review

References (79)

1. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation of the heart in diabetes: part I: general concepts. Circulation 2002;105:1727-33.
2. Young ME, McNulty P, Taegtmeyer H. Adaptation and maladaptation of the heart in diabetes: part II: potential mechanisms. Circulation 2002;105:1861-70.
3. Neubauer S. The failing heartean engine out of fuel. N Engl J Med 2007;356:1140-51.
4. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-9.
5. Bing RJ, Siegel A, Vitale A, et al. Metabolic studies on the human heart in vivo. I. Studies on carbohydrate metabolism of the human heart. Am J Med 1953;15:284-96.
6. Slot JW, Geuze HJ, Gigengack S, et al. Translocation of the glucose transporter GLUT4 in cardiac myocytes of the rat. Proc Natl Acad Sci U S A 1991;88:7815-19. (Pubitemid 21915245)
7. Sun D, Nguyen N, DeGrado TR, et al. Ischemia induces translocation of the insulinresponsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 1994;89:793-8. (Pubitemid 24056208)
8. Hue L, Depre C, Lefebvre V, et al. Regulation of glucose metabolism in cardiac muscle. Biochem Soc Trans 1995;23:311-14.
9. Jeremy RW, Koretsune Y, Marban E, et al. Relation between glycolysis and calcium homeostasis in postischemic myocardium. Circ Res 1992;70:1180-90.
10. Fuller W, Parmar V, Eaton P, et al. Cardiac ischemia causes inhibition of the Na/K ATPase by a labile cytosolic compound whose production is linked to oxidant stress. Cardiovasc Res 2003;57:1044-51.
11. Stanley WC. Myocardial lactate metabolism during exercise. Med Sci Sports Exerc 1991;23:920-4.
12. Gertz EW, Wisneski JA, Neese R, et al. Myocardial lactate metabolism: evidence of lactate release during net chemical extraction in man. Circulation 1981;63:1273-9. (Pubitemid 11120662)
13. Randle PJ. Fuel selection in animals. Biochem Soc Trans 1986;14:799-806.
14. Cottin Y, Lhuillier I, Gilson L, et al. Glucose insulin potassium infusion improves systolic function in patients with chronic ischemic cardiomyopathy. Eur J Heart Fail 2002;4:181-4.
15. Hermann HP, Pieske B, Schwarzmuller E, et al. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999;353:1321-3.
16. Liedtke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-36.
17. Hutter JF, Piper HM, Spieckerman PG. Effect of fatty acid oxidation on efficiency of energy production in rat heart. Am J Physiol 1985;249:H723-8.
18. Murray AJ, Anderson RE, Watson GC, et al. Uncoupling proteins in human heart. Lancet 2004;364:1786-8.
19. Finck BN, Kelly DP. Peroxisome proliferator-activated receptor alpha (PPARalpha) signaling in the gene regulatory control of energy metabolism in the normal and diseased heart. J Mol Cell Cardiol 2002;34:1249-57.
20. Koonen DP, Glatz JF, Bonen A, et al. Long-chain fatty acid uptake and FAT/CD36 translocation in heart and skeletal muscle. Biochim Biophys Acta 2005;1736:163-80.
21. Ibrahimi A, Bonen A, Blinn WD, et al. Muscle-specific overexpression of FAT/CD36 enhances fatty acid oxidation by contracting muscle, reduces plasma triglycerides and fatty acids, and increases plasma glucose and insulin. J Biol Chem 1999;274:26761-6.
22. Opie LH. The heart physiology, metabolism, pharmacology, and therapy. London: Grune & Stratton, 1984.
23. Bonnet D, Martin D, Pascale DL, et al. Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children. Circulation 1999;100:2248-53.
24. Mathur A, Sims HF, Gopalakrishnan D, et al. Molecular heterogeneity in very-longchain acyl-CoA dehydrogenase deficiency causing pediatric cardiomyopathy and sudden death. Circulation 1999;99:1337-43. (Pubitemid 29129919)
25. Strauss AW, Powell CK, Hale DE, et al. Molecular basis of human mitochondrial very-long-chain acyl-CoA dehydrogenase deficiency causing cardiomyopathy and sudden death in childhood. Proc Natl Acad Sci USA 1995;92:10496-500.
26. Young LH, Renfu Y, Russell R, et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997;95:415-22. (Pubitemid 27056209)
27. Bolukoglu H, Goodwin GW, Guthrie PH, et al. Metabolic fate of glucose in reversible low-flow ischemia of the isolated working rat heart. Am J Physiol 1996;270:H817-26.
28. Stanley WC. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron Artery Dis 2001 Feb;12 (Suppl. 1):S3-7.
29. Sorokina N, O'Donnell JM, McKinney RD, et al. Recruitment of compensatory pathways to sustain oxidative flux with reduced carnitine palmitoyltransferase I activity characterizes inefficiency in energy metabolism in hypertrophied hearts. Circulation 2007;115:2033-41.
30. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-129.
31. Taylor M, Wallhaus TR, DeGrado TR, et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F] FDG in Patients with Congestive Heart Failure. J Nucl Med 2001;42:55-62. (Pubitemid 32104778)
32. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001;88:529-35. (Pubitemid 32240917)
33. Marin-Garcia J, Goldenthal MJ, Moe GW. Mitochondrial pathology in cardiac failure. Cardiovasc Res 2001;49:17-26.
34. Liao R, Nascimben L, Friedrich J, et al. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Circ Res 1996;78:893-902.
35. Wallhaus TR, Taylor M, DeGrado TR, et al. Myocardial free fatty acid and glucose use after carvedilol treatment in patients with congestive heart failure. Circulation 2001;103:2441-6. (Pubitemid 32493369)
36. Bouche P, Bousser MG, Peytour MA, et al. Perhexiline maleate and peripheral neuropathy. Neurology 1979;29:739-43.
37. Roberts RK, Cohn D, Petroff V, et al. Liver disease induced by perhexiline maleate. Med J Aust 1981;2:553-4. (Pubitemid 12139318)
38. Horowitz JD, Sia ST, Macdonald PS, et al. Perhexiline maleate treatment for severe angina pectoris-correlations with pharmacokinetics. Int J Cardiol 1986;13:219-29.
39. Horowitz JD, Mashford ML. Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust 1979;1:485-8.
40. Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation 1990;81:1260-70.
41. Kennedy JA, Kiosoglous AJ, Murphy GA, et al. Effect of perhexiline and oxfenicine on myocardial function and metabolism during low-flow ischemia/reperfusion in the isolated rat heart. J Cardiovasc Pharmacol 2000;36:794-801.
42. Kantor PF, Lucien A, Kozak R, et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-8.
43. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Trimetazidine European multicenter study group. Br J Clin Pharmacol 1994;37:279-88.
44. la-Volta S, Maraglino G, la-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990;4 (Suppl 4):853-9.
45. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82.
46. Maier LS. A novel mechanism for the treatment of angina, arrhythmias, and diastolic dysfunction: inhibition of late I(Na) using ranolazine. J Cardiovasc Pharmacol 2009;54:279-86.
47. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35. (Pubitemid 30479390)
48. Holubarsch CJ, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007;113:205-12.
49. Cave AC, Ingwall JS, Friedrich J, et al. ATP synthesis during low-flow ischemia: influence of increased glycolytic substrate. Circulation 2000;101:2090-6.
50. Hess ML, Okabe E, Poland J, et al. Glucose, insulin, potassium protection during the course of hypothermic global ischemia and reperfusion: a new proposed mechanism by the scavenging of free radicals. J Cardiovasc Pharmacol 1983;5:35-43. (Pubitemid 13177948)
51. Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005 Jan 26;293:437-46.
52. Malmberg K, Ryden L, Hamsten A, et al. Effects of insulin treatment on causespecific one-year mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI study group. diabetes insulin-glucose in acute myocardial infarction. Eur Heart J 1996;17:1337-44.
53. Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005;26:650-61.
54. Labrou A, Giannoglou G, Zioutas D, et al. Trimetazidine administration minimizes myocardial damage and improves left ventricular function after percutaneous coronary intervention. Am J Cardiovasc Drugs 2007;7:143-50.
55. Willoughby SR, Stewart S, Chirkov YY, et al. Beneficial clinical effects of perhexiline in patients with stable angina pectoris and acute coronary syndromes are associated with potentiation of platelet responsiveness to nitric oxide. Eur Heart J 2002;23:1946-54.
56. Ashrafian H, Frenneaux MP. Metabolic modulation in heart failure: the coming of age. Cardiovasc Drugs Ther 2007;21:5-7.
57. Taegtmeyer H. Cardiac metabolism as a target for the treatment of heart failure. Circulation 2004;110:894-6.
58. Neubauer S, Krahe T, Schindler R, et al. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992;86:1810-18.
59. Neubauer S, Horn M, Cramer M, et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997;96:2190-6. (Pubitemid 27425822)
60. Witteles RM, Tang WH, Jamali AH, et al. Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 2004;44:78-81.
61. Witteles RM, Fowler MB. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 2008;51:93-102.
62. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-506.
63. Freeman DJ, Norrie J, Sattar N, et al. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the west of scotland coronary prevention study. Circulation 2001;103:357-62.
64. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.
65. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. the heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:145-53.
66. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a metaanalysis of randomised clinical trials. Lancet 2007;370:1129-36.
67. Phan TT, Shivu GN, Choudhury A, et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail 2009;11:881-6.
68. Lee L, Campbell R, Scheuermann-Freestone M, et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112:3280-8.
69. Fragasso G, Perseghin G, De CF, et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942-8.
70. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-21.
71. Rosano GM, Vitale C, Sposato B, et al. Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebocontrolled study. Cardiovasc Diabetol 2003;2:16.
72. Di NP, Taccardi AA, Barsotti A. Long term cardioprotective action of trimetazidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161-5.
73. Tuunanen H, Engblom E, Naum A, et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy. Circulation 2008;118:1250-8.
74. Dyck JR, Lopaschuk GD. Malonyl CoA control of fatty acid oxidation in the ischemic heart. J Mol Cell Cardiol 2002;34:1099-109.
75. Stanley WC, Morgan EE, Huang H, et al. Malonyl-CoA decarboxylase inhibition suppresses fatty acid oxidation and reduces lactate production during demandinduced ischemia. Am J Physiol Heart Circ Physiol 2005;289:H2304-9.
76. Dyck JR, Hopkins TA, Bonnet S, et al. Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 2006;114:1721-8.
77. Kolterman OG, Buse JB, Fineman MS, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9.
78. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008;117:2340-50.
79. Sokos GG, Nikolaidis LA, Mankad S, et al. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 2006;12:694-9.